Item 8.01 Other Events.

On June 16, 2021, Blueprint Medicines Corporation (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") approved the Company's supplemental new drug application for AYVAKIT™ (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.




Item 9.01  Financial Statements and Exhibits.



(d) Exhibits.



Exhibit No.    Description
  99.1           Press release issued by Blueprint Medicines Corporation
               on June 16, 2021
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document and incorporated as Exhibit 101)

© Edgar Online, source Glimpses